Statin Rx-To-Oh-We’ll See: Bristol’s Dolan Guarded On Pravachol Switch
This article was originally published in The Tan Sheet
Executive Summary
Broad regulatory concerns over drug safety across classes reduce the chances of an Rx-to-OTC statin switch, according to Bristol-Myers Squibb CEO Peter Dolan
You may also be interested in...
Bristol Consumer Unit Suitors Tasked With Determining Value Of Excedrin
Bristol-Myers Squibb says it will contact potential buyers for its North American Consumer Medicines division "over the coming weeks.
Bristol Consumer Unit Suitors Tasked With Determining Value Of Excedrin
Bristol-Myers Squibb says it will contact potential buyers for its North American Consumer Medicines division "over the coming weeks.
Bristol Consumer Unit Suitors Tasked With Determining Value Of Excedrin
Bristol-Myers Squibb says it will contact potential buyers for its North American Consumer Medicines division "over the coming weeks.